Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma

Journal of Surgical Oncology

Volumn 103, Issue 8, 2011, Pages 773-781

  Teng, Hao Wei ^a,b   Wang, Hsei Wei ^b   Chen, Wei Ming ^a,b   Chao, Ta Chung ^a,b   Hsieh, Yao Yu ^a,b   Hsih, Chi Hsiu ^a,b   Tzeng, Cheng Hwai ^a,b   Chen, Paul Chih Hsueh ^a   Yen, Chueh Chuan ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

BRAF; EGFR; KRAS; PI3KCA; PTEN; synovial sarcoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAF GENE; CHILD; CLINICAL ARTICLE; FEMALE; GENE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; ONCOGENE; ONCOGENE K RAS; OVERALL SURVIVAL; PI3KCA GENE; POINT MUTATION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PTEN GENE; SEQUENCE ANALYSIS; SYNOVIAL SARCOMA;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CHILD; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENE DELETION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PREVALENCE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SARCOMA, SYNOVIAL; SEQUENCE ANALYSIS, PROTEIN; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 79955695047     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21852     Document Type: Article

References (49)

1. Sandberg AA, Bridge JA:, Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Synovial sarcoma. Cancer Genet Cytogenet 2002; 133: 1-23. (Pubitemid 34228877)
2. Okcu MF, Despa S, Choroszy M, et al.: Synovial sarcoma in children and adolescents: Thirty three years of experience with multimodal therapy. Med Pediatr Oncol 2001; 37: 90-96. (Pubitemid 32738068)
3. Hasegawa T, Yokoyama R, Matsuno Y, et al.: Prognostic significance of histologic grade and nuclear expression of beta-catenin in synovial sarcoma. Hum Pathol 2001; 32: 257-263. (Pubitemid 32246798)
4. Spurrell EL, Fisher C, Thomas JM, et al.: Prognostic factors in advanced synovial sarcoma: An analysis of 104 patients treated at the Royal Marsden Hospital. Ann Oncol 2005; 16: 437-444. (Pubitemid 40458321)
5. Fisher C:, Synovial sarcoma: Ultrastructural and immunohistochemical features of epithelial differentiation in monophasic and biphasic tumors. Hum Pathol 1986; 17: 996-1008. (Pubitemid 17180634)
6. Thomas DG, Giordano TJ, Sanders D, et al.: Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 2005; 103: 830-838. (Pubitemid 40216413)
7. Tawbi H, Thomas D, Lucas DR, et al.: Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist 2008; 13: 459-466. (Pubitemid 351679927)
8. Barbashina V, Benevenia J, Aviv H, et al.: Oncoproteins and proliferation markers in synovial sarcomas: A clinicopathologic study of 19 cases. J Cancer Res Clin Oncol 2002; 128: 610-616. (Pubitemid 35435558)
9. Bonner JA, Harari PM, Giralt J, et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578. (Pubitemid 43209104)
10. Pirker R, Pereira JR, Szczesna A, et al.: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 2009; 373: 1525-1531.
11. Mok TS, Wu YL, Thongprasert S, et al.: Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
12. Van CE, Kohne CH, Hitre E, et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
13. Bokemeyer C, Bondarenko I, Makhson A, et al.: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671.
14. Siena S, Sartore-Bianchi A, Di NF, et al.: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101: 1308-1324.
15. Sartore-Bianchi A, Di NF, Nichelatti M, et al.: Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS ONE 2009; 4: e7287.
16. Roth AD, Tejpar S, Delorenzi M, et al.: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-474.
17. Ogino S, Nosho K, Kirkner GJ, et al.: PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009; 27: 1477-1484.
18. Barault L, Veyrie N, Jooste V, et al.: Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008; 122: 2255-2259. (Pubitemid 351542328)
19. Farina-Sarasqueta A, van LG, Moerland E, et al.: The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010; 21: 2396-2402.
20. Fletcher CDM, Unni KK, Mertens F:, Pathology and genetics of tumour of soft tissue and bone. Lyon, France: IARC Press; 2002.
21. Chen PC, Chang YH, Yen CC, et al.: Primary renal synovial sarcoma with inferior vena cava and right atrium invasion. Int J Urol 2003; 10: 657-660. (Pubitemid 38030615)
22. Mullen JR, Zagars GK:, Synovial sarcoma outcome following conservation surgery and radiotherapy. Radiother Oncol 1994; 33: 23-30. (Pubitemid 24362141)
23. Dobashi Y, Takei N, Suzuki S, et al.: Aberration of epidermal growth factor receptor expression in bone and soft-tissue tumors: Protein overexpression, gene amplification and activation of downstream molecules. Mod Pathol 2004; 17: 1497-1505. (Pubitemid 39627076)
24. Samowitz WS, Sweeney C, Herrick J, et al.: Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005; 65: 6063-6069.
25. Moroni M, Veronese S, Benvenuti S, et al.: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol 2005; 6: 279-286. (Pubitemid 40590264)
26. Baldus SE, Schaefer KL, Engers R, et al.: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010; 16: 790-799.
27. Liu J, Babaian DC, Liebert M, et al.: Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens. Mol Carcinog 2000; 29: 143-150.
28. Minaguchi T, Yoshikawa H, Oda K, et al.: PTEN mutation located only outside exons 5, 6 and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin Cancer Res 2001; 7: 2636-2642. (Pubitemid 32911365)
29. Gusterson B, Cowley G, McIlhinney J, et al.: Evidence for increased epidermal growth factor receptors in human sarcomas. Int J Cancer 1985; 36: 689-693. (Pubitemid 16211472)
30. Terry J, Lubieniecka JM, Kwan W, et al.: Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. Clin Cancer Res 2005; 11: 5631-5638. (Pubitemid 41060842)
31. Jones S, Zhang X, Parsons DW, et al.: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806.
32. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
33. Oda Y, Sakamoto A, Satio T, et al.: Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma. Mod Pathol 2000; 13: 994-1004.
34. Jin Y, Shima Y, Furu M, et al.: Absence of oncogenic mutations of RAS family genes in soft tissue sarcomas of 100 Japanese patients. Anticancer Res 2010; 30: 245-251.
35. Pignochino Y, Grignani G, Cavalloni G, et al.: Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 2009; 8: 118.
36. Barretina J, Taylor BS, Banerji S, et al.: Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010; 42: 715-721.
37. Chalhoub N, Baker SJ:, PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 2009; 4: 127-150.
38. Saito T, Oda Y, Kawaguchi K, et al.: PTEN and other tumor suppressor gene mutations as secondary genetic alterations in synovial sarcoma. Oncol Rep 2004; 11: 1011-1015.
39. Su L, Cheng H, Sampaio AV, et al.: EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor. Oncogene 2010; 29: 4352-4361.
40. Liu CY, Yen CC, Chen WM, et al.: Soft tissue sarcoma of extremities: The prognostic significance of adequate surgical margins in primary operation and reoperation after recurrence. Ann Surg Oncol 2010; 17: 2102-2111.
41. Lahat G, Tuvin D, Wei C, et al.: New perspectives for staging and prognosis in soft tissue sarcoma. Ann Surg Oncol 2008; 15: 2739-2748.
42. Gronchi A, Miceli R, Fiore M, et al.: Extremity soft tissue sarcoma: Adding to the prognostic meaning of local failure. Ann Surg Oncol 2007; 14: 1583-1590. (Pubitemid 46791007)
43. Inagaki H, Nagasaka T, Otsuka T, et al.: Association of SYT-SSX fusion types with proliferative activity and prognosis in synovial sarcoma. Mod Pathol 2000; 13: 482-488. (Pubitemid 30332098)
44. Kawai A, Woodruff J, Healey JH, et al.: SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 1998; 338: 153-160. (Pubitemid 28041862)
45. Ladanyi M, Antonescu CR, Leung DH, et al.: Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: A multi-institutional retrospective study of 243 patients. Cancer Res 2002; 62: 135-140. (Pubitemid 34073997)
46. Mezzelani A, Mariani L, Tamborini E, et al.: SYT-SSX fusion genes and prognosis in synovial sarcoma. Br J Cancer 2001; 85: 1535-1539. (Pubitemid 34001586)
47. Canter RJ, Qin LX, Maki RG, et al.: A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res 2008; 14: 8191-8197.
48. Guillou L, Benhattar J, Bonichon F, et al.: Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: A multicenter, retrospective analysis. J Clin Oncol 2004; 22: 4040-4050. (Pubitemid 41185173)
49. Takenaka S, Ueda T, Naka N, et al.: Prognostic implication of SYT-SSX fusion type in synovial sarcoma: A multi-institutional retrospective analysis in Japan. Oncol Rep 2008; 19: 467-476. (Pubitemid 351176109)